Business Context and Reporting Period
This Form 8-K filing by Atyr Pharma, Inc. (ticker: LIFE) is dated February 7, 2019. The report addresses a change in the listing status of the Company's common stock on The Nasdaq Stock Market.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on regulatory listing status rather than financial performance metrics.
Material Changes
- Listing Transfer: Nasdaq approved the transfer of the Company's common stock from the Nasdaq Global Select Market to the Nasdaq Capital Market, effective February 11, 2019.
- Reason for Transfer: The transfer follows a notice received on August 9, 2018, stating the stock price closed below the $1.00 minimum bid price requirement for 30 consecutive trading days.
- Grace Period: The Company was granted an additional 180-day grace period ending August 5, 2019, to regain compliance.
Outlook, Risks, and Contingencies
- Compliance Requirement: To maintain listing on the Nasdaq Capital Market, the stock must trade at or above $1.00 per share for at least ten consecutive business days during the grace period.
- Delisting Risk: Failure to regain compliance by August 5, 2019, will result in delisting by Nasdaq.
- Contingency Plan: The Company has notified Nasdaq of its intention to cure the deficiency, potentially through a reverse stock split if necessary.
- Trading Symbol: The stock will continue to trade under the symbol "LIFE".
Investor Verification Checklist
- Verify the current trading price of "LIFE" to assess proximity to the $1.00 compliance threshold.
- Monitor upcoming announcements regarding the potential execution of a reverse stock split.
- Confirm the effective date of the listing transfer (February 11, 2019) and any associated trading halts or changes.
- Review the Company's cash position in subsequent filings to determine if a reverse stock split is financially viable or if capital raising is required.